搜索
Galmed Pharmaceuticals Ltd
GLMD添加自选
0.570USD
-0.079-12.34%
收盘 07/02, 13:00（美东）报价延迟15分钟
3.75M总市值
亏损市盈率 TTM
关于 Galmed Pharmaceuticals Ltd 公司
Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
Galmed Pharmaceuticals Ltd简介
公司代码GLMD
公司名称Galmed Pharmaceuticals Ltd
上市日期Mar 13, 2014
CEOBaharaff (Allen)
员工数量3
证券类型Ordinary Share
年结日Mar 13
公司地址16 Tiomkin Street
城市TEL AVIV-YAFO
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Israel
邮编6578317
电话97236938448
网址https://www.galmedpharma.com
公司代码GLMD
上市日期Mar 13, 2014
CEOBaharaff (Allen)
Galmed Pharmaceuticals Ltd公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Allen Baharaff
Mr. Allen Baharaff
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
127.23K
+70.97%
Mr. Yohai Stenzler, CPA
Mr. Yohai Stenzler, CPA
Chief Accounting Officer
Chief Accounting Officer
27.95K
+77.52%
Mr. Guy Nehemya
Mr. Guy Nehemya
Chief Operating Officer, Data Protection Officer
Chief Operating Officer, Data Protection Officer
27.95K
+77.52%
Mr. Doron Cohen
Mr. Doron Cohen
Chief Financial Officer
Chief Financial Officer
27.92K
+77.61%
Mr. Shmuel Nir
Mr. Shmuel Nir
Independent Director
Independent Director
14.23K
+76.14%
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Lead Independent Director
Lead Independent Director
14.00K
+77.69%
Mr. Amir Poshinski
Mr. Amir Poshinski
Independent Director
Independent Director
13.96K
+77.62%
Dr. Liat Hayardeny, Ph.D.
Dr. Liat Hayardeny, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Carol L. Brosgart, M.D.
Dr. Carol L. Brosgart, M.D.
Independent Director
Independent Director
--
--
Mr. Marshall A. Heinberg, J.D.
Mr. Marshall A. Heinberg, J.D.
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Allen Baharaff
Mr. Allen Baharaff
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
127.23K
+70.97%
Mr. Yohai Stenzler, CPA
Mr. Yohai Stenzler, CPA
Chief Accounting Officer
Chief Accounting Officer
27.95K
+77.52%
Mr. Guy Nehemya
Mr. Guy Nehemya
Chief Operating Officer, Data Protection Officer
Chief Operating Officer, Data Protection Officer
27.95K
+77.52%
Mr. Doron Cohen
Mr. Doron Cohen
Chief Financial Officer
Chief Financial Officer
27.92K
+77.61%
Mr. Shmuel Nir
Mr. Shmuel Nir
Independent Director
Independent Director
14.23K
+76.14%
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Lead Independent Director
Lead Independent Director
14.00K
+77.69%
常见问题
Galmed Pharmaceuticals Ltd的前五大股东是谁？
Galmed Pharmaceuticals Ltd 的前五大股东如下：Mr. Allen Baharaff
有多少机构持有Galmed Pharmaceuticals Ltd(GLMD)的股份？
截至2026Q1，共有30家机构持有Galmed Pharmaceuticals Ltd的股份，合计持有的股份价值约为224.38K，占公司总股份的3.40%。与2025Q4相比，机构持股有所增加，增幅为75169.00。